ROSWELL, Ga., and WESTBROOK, Maine, June 5, 2020 /PRNewswire/ -- OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that it has received the CE mark ...
CLEVELAND, OH, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company advancing portal-hepatic ...
The OPTI-2 trial is a randomized, double-blind study that will enroll 220 participants to be followed over a six-month treatment period. Study subjects will utilize the Dexcom G7 Continuous Glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results